Neumedicines announces results of HemaMax study

The privately-held Neumedicines, Inc., recently announced results for a study of HemaMax (rHuIL-12), which is being developed as a prophylactic and frontline post-exposure therapeutic for the treatment of the Hematopoietic Syndrome of Acute Radiation Syndrome.

HemaMex was compared with vehicle, granulocyte-colony stimulating factor (G-CSF), or rHuIL-12+G-CSF, following lethal irradiation in rhesus monkeys in a GLP, randomized, blinded, placebo-controlled study.

The study found that survival at 60 days was increased significantly for rHuIL-12 versus G-CSF or vehicle. No additional survival benefit was found for the combination for rHuIl-12 and G-CSF compared to rHuIl-12 alone. rHuIl-12 was found to increase blood cell nadirs and induce earlier recovery of all hematopoietic lineages while significantly decreasing frequencies of severe cytopenias versus vehicle or G-CSF.

rHuIl-12 increased erythroid, myeloid and megakaryoctye counts in bone marrow relative to vehicle or G-CSF, with a single rHuIl-12 injection without supportive medical intervention significantly improving survival and promoting multilineage hematopoietic recovery in a nonhuman primate model.

"Recombinant interleukin-12, but not granulocyte-colony stimulating factor, improves survival in lethally irradiated non-human primates in the absence of supportive care: evidence for the development of a frontline radiation medical countermeasure," Neumedicines said.